TIDMONC
RNS Number : 4536U
Oncimmune Holdings PLC
06 April 2021
6(th) April 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Agreements signed with Roche and Cedars-Sinai to profile
patients using Oncimmune's novel Infectious Disease panel
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, today announces that it has signed two
separate agreements with Roche Pharmaceuticals ("Roche") and
Cedars-Sinai Medical Center ("Cedars-Sinai"), in each case to use
the Company's newly developed and proprietary Infectious Disease
panel.
O n 6 October 2020, Oncimmune announced the award of UK
Government funding for the development and validation of an
Infectious Disease NavigAID(TM) panel under the IMmunity Profiling
of pAtients with COVID-19 for Therapy and Triage ("IMPACTT")
programme. Utilising the data from this and other work, the
Company's current SeroTag(TM) research panel has been tailored to
predict COVID-19 disease severity and therapeutic response to the
virus and the effectiveness of vaccines and other repurposed
therapeutics as treatment against the disease. Both of these
substantial new contracts will utilise this research tool to
profile patient samples in search of immune related signatures in
COVID-19 patients.
For Roche, Oncimmune will utilise its Infectious Disease panel
to profile antibody and autoantibody responses in all patient
samples from the Roche COVACTA trial, to look for immune signals of
response, non-response and adverse events. The COVACTA trial was
set up to evaluate the safety and efficacy of tocilizumab in
patients with severe COVID-19 pneumonia. The contract also includes
an option to extend to IgA and IgM antibody profiling which will
substantially increase the value of the contract.
In October 2020, Oncimmune also announced that it had entered
into an agreement with Cedars-Sinai in Los Angeles, a world-leading
medical research organisation, to provide antibody profiling in
COVID-19 samples as biomarkers for this disease. Following on from
this first project, Cedars-Sinai has agreed to expand its
collaborative COVID-19 programme to study a unique cohort of
patients.
Dr Adam M Hill, CEO of Oncimmune said: "We are delighted to be
strengthening our partnership with Roche and Cedars-Sinai through
these two very important projects. As the world shifts its focus to
recovering from the pandemic, we are seeing continued interest in
Oncimmune's infectious disease offering. Today's announcement is
further validation of the importance of our Infectious Disease
panel in supporting both clinical research and the development of
vaccines and therapeutics. We are also experiencing substantial
interest in our immuno-oncology and autoimmune activities, which
together with our infectious disease offering, provides us with
confidence in the continued growth of ImmunoINSIGHTS."
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. Oncimmune has a diversified and
growing revenue from its portfolio of diagnostic products to detect
early-stage cancer and a contract discovery and development
service-based platform, delivering actionable insights into
therapies to its pharmaceutical and biotech partners .
Our intimate understanding of the human immune system enables us
to harness its sophisticated response to disease to detect cancer
earlier and to support the development of better therapies. The key
to improving cancer survival is early detection and better
selection for therapy. As a company, we are driven by our passion
to improve cancer survival and to give people extra time.
Oncimmune's ImmunoINSIGHTS platform enables life science
organisations to optimise drug development and delivery, leading to
more effective targeted as well as safer treatments for patients.
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and
help identify cancer on average four years earlier than standard
clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to GBP3.8bn by 2024. With
over 200,000 tests already performed for patients worldwide and its
use being supported by peer reviewed data in over 12,000 patients,
we are poised to become an integral component of future lung cancer
detection programmes, globally.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, and has a discovery research centre in Dortmund,
Germany.
For more information, visit www.oncimmune.com
What is ImmunoINSIGHTS?
The ImmunoINSIGHTS service business leverages Oncimmune's
technology platform and methodologies across multiple diseases, to
offer life-science organisations actionable insights for therapies
across the development and product lifecycle. Our core
immune-profiling technology is underpinned by our library of over
eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into
clinically relevant subgroups, enabling development of targeted and
more effective treatments.
What is NavigAID (TM) ?
Oncimmune's NavigAID arrays are thoroughly validated containing
well defined antigen panels, largely encompassing markers of
interest for each of the disease types being investigated.
Our portfolio of panels includes out-of-the-box NavigAID arrays
for immuno-oncology and autoimmune diseases. These validated panels
are frequently used as the starting point for collaborations with
partners to add further markers of interest to their specific
therapy and its specific indication.
What is SeroTag (TM) ?
Oncimmune's proprietary biomarker discovery engine, which is
leveraged in our ImmunoINSIGHTS services to discover and validate
novel biomarkers can help stratify patients in multiple cancer
indications and with different autoimmune diseases.
This high-throughput, multiplex technology is based on one of
the largest, in-house protein libraries, as well as a unique,
ever-growing repository of disease data for indications including,
but not limited to, autoimmune diseases and cancer. As a result,
SeroTag is helping to address and monitor a number of challenges
currently hindering the successful development and broader
application of both cancer immunotherapies and treatments for
autoimmune diseases.
The platform is being applied to discover and validate
biomarkers and develop precision diagnostic tools from minimally
invasive liquid biopsies. SeroTag analyses autoantibodies-some of
the most stable analytes-and is used most frequently for the
identification of IgG isoforms, in addition to IgM and IgA, from
just a few drops of serum.
The SeroTag platform acts as the primary discovery engine that
feeds into the creation of Oncimmune's NavigAID disease-specific
stratification panels-precision medicine tools which are enabling
patient and disease stratification and support therapeutic
development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRDGGDSCSGDGBU
(END) Dow Jones Newswires
April 06, 2021 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024
